Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Theravance Biopharma (TBPH) Receivables - Other (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Receivables - Other for 13 consecutive years, with $45.5 million as the latest value for Q4 2025.

  • Quarterly Receivables - Other rose 146.96% to $45.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.5 million through Dec 2025, up 146.96% year-over-year, with the annual reading at $45.5 million for FY2025, 146.96% up from the prior year.
  • Receivables - Other for Q4 2025 was $45.5 million at Theravance Biopharma, up from $18.3 million in the prior quarter.
  • The five-year high for Receivables - Other was $45.5 million in Q4 2025, with the low at $11.9 million in Q1 2021.
  • Average Receivables - Other over 5 years is $20.2 million, with a median of $16.8 million recorded in 2022.
  • The sharpest move saw Receivables - Other crashed 71.37% in 2021, then skyrocketed 198.44% in 2022.
  • Over 5 years, Receivables - Other stood at $42.5 million in 2021, then crashed by 60.5% to $16.8 million in 2022, then rose by 4.1% to $17.5 million in 2023, then rose by 5.53% to $18.4 million in 2024, then surged by 146.96% to $45.5 million in 2025.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $45.5 million, $18.3 million, and $21.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.